Data / Drug companies / Norelgestromin and ethinyl estradiol
Norelgestromin and ethinyl estradiol: 8 companies and 8 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Norelgestromin and ethinyl estradiol is listed in the FDA National Drug Code Directory by 8 companies, with 8 products in commercial distribution. 7 of the products (87.5%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are patch, and the newest product started marketing on October 1, 2026.
The request: Get every company that lists norelgestromin and ethinyl estradiol in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 8
- Products
- 8
- Generic (ANDA) products
- 7 (87.5%)
- Application numbers
- 4
- Routes
- Transdermal
- Brand names
- Zafemy, Xulane, Gwyn Lo
- openFDA record search
- api.fda.gov
Companies that list norelgestromin and ethinyl estradiol
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 1 | patch | Generic drugs (ANDA) | April 16, 2014 |
| Amneal Pharmaceuticals LLC | 1 | patch | Generic drugs (ANDA) | June 28, 2020 |
| AvKARE | 1 | patch | Generic drugs (ANDA) | May 15, 2023 |
| Bryant Ranch Prepack | 1 | patch | Generic drugs (ANDA) | June 28, 2020 |
| Mylan Pharmaceuticals Inc. | 1 | patch | Generic drugs (ANDA) | April 16, 2014 |
| Viatris Specialty LLC | 1 | patch | New drug applications (NDA) | October 1, 2026 |
| Zydus Lifesciences Limited | 1 | patch | Generic drugs (ANDA) | November 21, 2023 |
| Zydus Pharmaceuticals USA Inc. | 1 | patch | Generic drugs (ANDA) | November 21, 2023 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Patch | 8 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 7 | 87.5% |
| New drug applications (NDA) | 1 | 12.5% |
Pharmacologic classes
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.